

Special Issue

Advances in the Treatment of Renal Cell Carcinoma

Message from the Guest Editors

Renal cell carcinoma (RCC) represents 90% of kidney cancers and around 3% of all malignancies worldwide. Established risk factors for RCC include increasing age, smoking, obesity, and hypertension. The incidence of RCC is rising, partly due to changes in the above risk factors and partly due to the increased detection of asymptomatic RCC by the widespread use of modern abdominal imaging techniques. While there has been a decrease in the number of patients presenting with advanced metastatic RCC, compared to early disease presentation, there remains the significant issue of clinical resistance to current therapies and drug resistance remains a significant health burden. This Special Issue will focus on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon. We look forward to your contributions.

Guest Editors

Dr. Paul Reynolds

School of Medicine, University of St Andrews, Medical and Biological Sciences Building, North Haugh, St Andrews KY16 9TF, UK

Mr. Grant D Stewart

Department of Surgery, University of Cambridge, Cambridge, CB2 0QQ, UK

Deadline for manuscript submissions

closed (30 September 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/35079

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)